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INTRODUCTION
After the publication of the landmark Veterans Affairs (VA) laryngeal cancer study and the Radiation Therapy Oncology Group (RTOG) 91-11 randomized trials, 1, 2 which demonstrated the viability of nonsurgical larynx preservation approaches, strategies using sequential or concurrent chemoradiotherapy (CRT) have increasingly been used for the definitive treatment of locally advanced laryngeal cancers. However, several studies' findings have implied that nonsurgical larynx preservation approaches may be associated with survival decrement. [3] [4] [5] [6] [7] Specifically, Hoffman et al, 3 using large-scale series from the National Cancer Data Base (NCDB), reported that the increased use of organ preservation approaches was associated with a decrement in relative survival in patients with T3 laryngeal cancer. Gourin et al, 4 in a retrospective series of locally advanced disease, demonstrated that nonsurgical larynx preservation was associated with poorer survival particularly for patients with T4 disease. In a retrospective series from the Alberta Cancer Registry, Dziegielewski et al 5 showed that patients with T3 as well as patients with T4a laryngeal cancer had inferior survival for both the radiation alone and the concurrent CRT cohorts compared to the surgical cohorts. Another NCDB analysis reported by Chen et al, 6 showed increased mortality risk among patients with T3 disease treated with nonsurgical approaches, particularly in patients treated by radiotherapy (RT) alone. More recently, Megwalu and Sikora, 7 analyzing grouped survival data from the Surveillance, Epidemiology, and End Results 18 registry, reported that patients with some T3 laryngeal cancers who were treated with surgery had better survival outcomes than those who were treated with nonsurgical management. These findings have led some researchers to question the utility of chemoradiation as first-line therapy for T3 laryngeal cancer. [3] [4] [5] [6] [7] This is not an invalid concern, as the VA and RTOG trials took place in an era before the introduction of modern RT techniques. The VA 1 and RTOG 2 studies, designed and conducted several decades ago, enrolled patients who were treated with nonvolumetric imaging-based conventional 2D or 3D CRT (2D/3D CRT). Since then, technical gains in RT techniques via CT-guided intensity-modulated radiotherapy (IMRT) have revolutionized the capacity for normal tissue sparing to such a degree that assessing data from the pre-IMRT era would be considered anachronistic, given published data demonstrating definitively the reduced toxicity and improved quality of life outcomes achieved with IMRT. [8] [9] [10] [11] [12] [13] Similarly, the improved survival outcomes provided by IMRT 14 suggest that grossly grouping 2D/3D CRT and IMRT in studying oncologic and functional outcomes provides a limited, if not specious, risk estimation in modern-day patients.
Given these considerations, the purpose of the present study was to use a robust dataset to investigate survival, disease control, and functional outcomes with modern larynx preservation approaches. We used our institutional historic RT-alone and total laryngectomy with the postoperative RT (TL-PORT) cohorts as comparators. We evaluated oncologic and functional outcomes for patients with T3 laryngeal cancer treated at our institution in the previous 3 decades and compared outcomes of the larynx preservation with induction and/or concurrent chemoradiotherapy (LP-CRT) cohorts with those of the historical surgical and nonsurgical cohorts.
MATERIALS AND METHODS
This retrospective chart review was approved by The University of Texas MD Anderson Cancer Center's Institutional Review Board. Sequential patients with locally advanced squamous cell carcinoma of the larynx who received RT with curative intent at MD Anderson Cancer Center between January 1, 1985, and December 31, 2011, were identified from an institutional registry. The paper and electronic records of all patients whose disease met the criteria for T3N0-3M0 squamous cell cancer of the larynx (per the seventh edition of the American Joint Committee on Cancer [AJCC] staging manual, 2010) were reviewed. Patients with distant metastasis at initial presentation and patients treated for salvage or palliative intents were excluded. Patient demographics, Eastern Cooperative Oncology Group (ECOG) performance status scores, tumor data (pathologic grade and subsite of origin), and clinical TNM staging data were extracted from patient records. TNM staging was manually reviewed and revised as necessary according to the seventh edition of the AJCC staging manual (eg, after the AJCC sixth edition, partial cartilage involvement is considered T3 disease whereas previous editions considered it as T4). Baseline pretreatment comorbidity data were collected and comorbidity score index was calculated for each case, as described by Charlson et al. 15 All extracted information was recorded in a database (SPSS; IBM, Chicago, IL). Staging findings from CT and/or positron emission tomography-CT were recorded, as were pathologic data from patients who had surgery as primary treatment; chemotherapy regimen(s) and their sequence with RT (induction, concurrent, or both); and RT dose, fractionation, technique, beam energy, and delivery technique. Biologically equivalent dose was calculated using the simple biologically equivalent dose equation without correction for repopulation. 16 Disease recurrence was coded as local recurrence (ie, occurring in the treated primary site), locoregional recurrence (ie, occurring in the treated primary site or treated lymph nodes), or distant metastases (ie, squamous carcinomas occurring outside the treated head and neck). Because records of distant metastases and second primary squamous carcinomas could not be reliably separated, these pathologies were grouped together as metastatic events in the current analysis. Cause of death was manually coded; patients with active cancer at the time of death were coded as having "cancer-related death," whereas patients without active disease at last follow-up were coded as having "noncancer death."
Survival endpoints
The Kaplan-Meier product limit method was used to calculate, from the date of diagnosis, rates of 5-year and 10-year overall survival (OS; defined as death from any cause as an event, all others censored), local control (defined as time without local recurrence, with local recurrence, or cancer in the larynx coded as an event, and all others censored), locoregional control (defined as time without locoregional disease, with local recurrence, or cancer in the treated fields coded as an event, and all others censored), freedom from distant disease (defined as time without disease outside the therapy field, with any cancer occurring outside the treated fields coded as an event, and all others censored), recurrence-free survival (RFS; defined as time without any recurrence, censoring all others, including deaths), cancer event-free survival (recurrence and death coded as events, all others censored), disease-specific survival (DSS; death from disease coded as an event and censoring all others). Three composite functional/mortality endpoints were calculated for patients who had larynx preservation: actuarial freedom from laryngectomy (FFL; in which salvage laryngectomy was coded as an event, censoring all others; laryngectomy-free survival (in which any death or salvage total laryngectomy were coded as events, censoring all others; and laryngoesophageal dysfunction-free survival (in which any death, local relapse, salvage total laryngectomy, tracheotomy, and/or feeding tube placement/persistence recorded after 2 years was coded as an event, censoring all others. Noncancer cause-specific survival (in which all deaths recorded in patients without active cancer at last follow-up were coded as events, and all others censored) was used as a crude estimator of noncancer mortality events.
Statistical analysis
Competing risk survival and hazard calculation were performed with Weibull parametric fitting using cause of death as a competing risk variable for uncensored data. For actuarial comparisons, the log-rank test was used. Univariate and multivariate Cox proportional hazards assessments were performed to determine whether the following variables were correlated with disease control and/ or survival endpoints: ECOG performance status score at treatment (0-4); age (as a continuous variable); nodal positivity (as a binary variable, N0 vs N1); sex (male or female); histologic grade (low, intermediate, or high); Charlson comorbidity index (as a continuous variable); the chemotherapy cohort (RT alone, induction/concurrent CRT); the surgery cohort (larynx preservation vs postlaryngectomy RT); and RT dose (as a continuous variable). After initial assessment, a second simplified multivariate model specifying dichotomized binary parameters was constructed for the following variables, using the second listed cohort as a comparator: ECOG performance status score (0 or 1 vs 2-4); age (<60 vs 60 years); nodal positivity (N0 vs N1); the surgery cohort (larynx preservation vs post-laryngectomy RT); sex (female vs male); and the chemotherapy cohort (induction/concurrent CRT vs RT alone). The simplified multivariate model was used to investigate all actuarial and survival endpoints using a 2-degree full factorial proportional hazards calculation, and the resultant calculated hazard ratio (HR) confidence intervals (CIs) were visually plotted as compared to the reference cohort.
Furthermore, product limit survival differences were interrogated for listed outcomes as a function of binary N category (ie, N0 vs N1). At our facility, for patients with T3 laryngeal cancer who were candidates for organ preservation, CRT and IMRT were consistently implemented together, as the use of IMRT occurred solely in the era in which larynx preservation strategies involved CRT. Owing to changing institutional treatment paradigms, patients were categorized into 3 broad therapy cohorts for Kaplan-Meier analysis: (1) total laryngectomy followed by postoperative RT (TL-PORT); (2) larynx preservation with definitive RT alone (LP-RT); and (3) larynx preservation with induction and/or concurrent CRT (LP-CRT). Univariate proportional hazards assessment was performed for all calculated endpoints stratified by the therapy cohort.
A post hoc assessment using univariate Cox proportional hazards for all calculated endpoints stratified by RT technique, chemotherapy use for larynx preservation patients, and by treatment decade (1980s, 1990s, and 2000s) was performed to assess the impact of IMRT or conventional RT, different CRT-RT sequences used in larynx preservation, and different era of treatment on disease control and survival. Data were analyzed using JMP 11.2 Pro statistical software (SAS Institute, Cary, NC), and statistical significance was determined using a specified non-Bonferroni-corrected a of 0.05.
RESULTS

Patient and treatment characteristics
A total of 417 sequential patients with previously untreated T3 laryngeal squamous cell carcinoma presented to our facility during the study period. Five patients had incomplete records and were excluded, leaving 412 patients for analysis. The patients' median age at diagnosis was 61 years (range, 30-88 years), and 287 patients (70%) were men. The overwhelming majority of tumors were of supraglottic origin (73%). Of the 287 patients (70%) who were treated using a larynx preservation approach, 166 (58%) received induction (n 5 53), concurrent (n 5 87), or both induction and concurrent (n 5 26) chemotherapy. Of the 125 patients (30%) who underwent TL-PORT, 113 (90%) received RT alone after total laryngectomy, and 12 (10%) received induction (n 5 7) or concurrent (n 5 5) chemotherapy. Patients' demographic data and treatment characteristics are given in Table 1 .
Survival endpoint analysis
The median follow-up duration was 57 months (range, 4-321 months) for all patients and 80 months (range, 6-307 months) for patients alive at last contact. The median OS duration was 73 months (95% CI 5 61-88 months). The 5-year and 10-year OS rates were 56% and 35%, respectively; the 5-year and 10-year DSS rates were 69% and 61%, respectively; the actuarial 5-year and 10- year local control probabilities were 84% and 82%, respectively; the 5-year and 10-year locoregional control rates were 78% and 76%, respectively; and the 5-year and 10-year freedom from distant disease rates were 84% and 83%, respectively (see Figure 1) .
Assessment of competing causes of survival for all patients revealed the late predominance of noncancer mortality, with noncancer-related death predominating approximately 8 years after diagnosis (Supplementary Figure S1 , online only). 
Correlates of survival
Therapy cohorts
The median follow-up times of the LP-CRT cohort (n 5 166; 60 months), the LP-RT cohort (n 5 121; 53 months), and the TL-PORT cohort (n 5 125; 56 months) did not differ significantly (p 5 .7). Charlson's comorbidity index was slightly higher in the LP-RT cohort (1 6 1.4) compared to the LP-CRT (0.7 6 1) and the TL-PORT (0.7 6 1) cohorts. The vast majority of patients in the 3 cohorts completed the prescribed radiation course within the planned treatment duration. Only 3 patients in the LP-RT, 6 in the LP-CRT, and 9 in the TL-PORT cohorts had >3 days of delay during radiation course. The details of demographics and disease characteristics in each therapy cohort are provided in Supplementary Table  S1 , online only.
Log-rank assessment of product limit survival revealed that the median survival duration of the LP-CRT cohort (102 months; 95% CI 5 79-126 months) was significantly higher than those of the TL-PORT cohort (61 months; 95% CI 5 42-82 months) and the LP-RT cohort (53 months; 95% CI 5 43-73 months; p 5 .006). The 5-year and 10-year OS rates of the LP-CRT cohort (67% and 43%, respectively) were higher than those of the TL-PORT cohort (50% and 35%, respectively), which were higher than those of the LP-RT cohort (46% and 25%, respectively).
Pairwise comparison of the 10-year locoregional control showed that the TL-PORT cohort was statistically better than the LP-RT cohort (83% vs 64%; p 5 .003) but only numerically better than the LP-CRT cohort (83% vs 77%; p 5 .2). Ultimately, 66% (n 5 23) and 58% (n 5 22) of the patients with local and/or regional failure in the LP-CRT and the LP-RT cohorts, respectively, underwent a subsequent salvage surgery after the initial recurrence that maintained the ultimate locoregional control (ie, no second locoregional relapse) in 48% (n 5 11) and 50% ; red boxplots represent increased probability of endpoint occurrence, whereas green boxplots indicate reduced risk of endpoint occurrence. OS, overall survival; LC, local control; LRC, locoregional control; ultimate LRC; FDD, freedom from distant disease; RFS, recurrence-free survival; EFS, cancer event-free survival; DSS, disease-specific survival; NCCSS), noncancer cause-specific survival (NCCSS). HRs were assessed for all patients (n 5 412). [Color figure can be viewed at wileyonlinelibrary.com] (n 5 11) of salvaged patients in the LP-CRT and the LP-RT cohorts, respectively. Consequently, the 10-year ultimate locoregional control rates of the TL-PORT, the LP-CRT, and the LP-RT cohorts (83%, 84%, and 74%, respectively) were not significantly different.
The 10-year freedom from distant disease rate of the TL-PORT cohort (71%) was significantly lower than those of the LP-RT cohort (90%) and the LP-CRT cohort (87%; p 5 .0005). The DSS was superior in the LP-CRT cohort (79% at 5 years and 73% at 10 years) compared to both the TL-PORT (61% at 5 years and 53% at 10 years) and the LP-RT (64% at 5 years and 56% at 10 years) cohorts (p 5 .002). All disease control and survival endpoints for the 3 therapy cohorts are presented in Figure 3 , whereas HRs and CIs are presented in Figure 4 .
Assessment of competing risks of failure and Weibull competing causes of failure revealed that the primary pattern of failure in the TL-PORT cohort was distant failure; the Weibull-estimated 10-year cumulative incidences of distant failure and locoregional failure were 32% and 18%, respectively. However, the primary pattern of failure in the LP-RT cohort was locoregional failure, which had a 10-year cumulative incidence of 40%, compared to a 20% for distant failure at the same time. In the LP-CRT cohort, the risks of locoregional and distant failure were similar, with a 10-year cumulative incidence of 23% for locoregional failure and 19% for distant failure (Figures 5A-5C ). Assessment of competing risks of survival revealed a relatively prolonged cancer-specific cause of death in the TL-PORT cohort for approximately 14 years postdiagnosis compared with the LP-CRT (approximately 6 years) and the LP-RT cohorts (approximately 5.5 years; Figures 5D-5F ). year laryngectomy-free survival rates of the LP-CRT cohort (62%; 95% CI 5 54% to 69%; and 37%; 95% CI 5 28% to 46%; respectively) were higher than those of the LP-RT cohort (38%; 95% CI 5 29% to 47%; and 18%; 95% CI 5 12% to 25%; respectively). Similarly, the 5-year and 10-year laryngoesophageal dysfunction-free survival rates of the LP-CRT cohort (59%; 95% CI 5 51% to 66%; and 35%; 95% CI 5 26% to 44%; respectively) were higher than those of the LP-RT cohort (37%; 95% CI 5 29% to 46%; and 18%; 95% CI 5 12% to 25%; respectively). The FFL of the LP-CRT cohort was higher than that of the LP-RT cohort, but this difference was not statistically significant (HR 5 0.71; 95% CI 5 0.4-1.3; p 5 .3). All composite endpoints are presented in Figure 6 .
Composite endpoints and functional outcomes
At last follow-up, the LP-CRT cohort had a tracheostomy rate of 20%, any-event aspiration rate of 22%, and a feeding tube rate of 15%, and the LP-RT cohort had a tracheostomy rate of 23%, any-event aspiration rate of 15%, and a feeding tube rate of 12%. Although the TL-PORT cohort had a permanent tracheostomy rate of 100%, it also had few aspiration events in 9% of patients caused by leakage around the voice prosthesis. The feeding tube rate was 10% in the TL-PORT cohort, which was not significantly different from those of the larynx preservation cohorts (p 5 .48). The long-term functional outcomes for the 3 therapy cohorts are shown in Table 2 .
Intensity-modulate radiotherapy versus 2D/3D chemoradiotherapy
Patients treated with larynx preservation approaches (n 5 287) were classified by RT technique to an IMRT cohort (n 5 61) or a 2D/3D CRT cohort (n 5 226). Compared with those in the 2D/3D CRT cohort, patients in the IMRT cohort had better locoregional control, laryngectomy-free survival, RFS, and event-free survival. Nonetheless, the median OS duration of the IMRT cohort (102 months; 95% CI 5 64-102 months) was not significantly different from that of the 2D/3D CRT cohort (73 months; 95% CI 5 59-93 months; p 5 .18; Figure 7) . The HRs for all endpoints for the IMRT cohort versus the 2D/3D CRT cohort are shown in Supplementary Figure  S2 , online only.
Chemotherapy
Patients who received concurrent CRT either after induction chemotherapy (n 5 26) or upfront (n 5 87) had better locoregional control and RFS than did patients who received induction chemotherapy followed by RT alone (n 5 53) or no chemotherapy (n 5 121; p 5 .02 for both locoregional control and RFS; Figures 8A and  8B) . The 3 cohorts that received chemotherapy had better OS than the cohort that did not receive chemotherapy (p 5 .0006; Figure 8C ). The results of a univariate Cox proportional hazards model for chemotherapy use in larynx preservation patients are shown in Supplementary  Figure S3 , online only. 
Treatment decade
Changes in the selection of alternative treatment options for patients with T3 laryngeal cancer in different decades elucidate the shifts in the preferred strategy over time in which TL-PORT was the most common in the 1980s (61%; n 5 53), LP-RT was the most common in the 1990s (43%; n 5 83), whereas LP-CRT was the most common in the new millennium (76%; n 5 101); Supplementary Table S1 , online only, shows the distribution of treatment strategies over different decades. The 5-year OS rates were 46%, 54%, and 65% for patients treated in 1980s, 1990s, and 2000s, respectively (p 5 .1; Supplementary Figure S4 
DISCUSSION
In this large-scale retrospective study, we found that age <60 years, better performance status, lower comorbidity index, node negative category, glottic subsite, and patients who received chemotherapy were all associated with improved OS for T3 laryngeal cancer. The ultimate locoregional control for patients treated using LP-CRT was equivalent to those treated using TL-PORT, and better than those treated using LP-RT. In addition, LP-CRT patients had better long-term survival outcomes with acceptable functional outcomes represented as 59% rate of laryngoesophageal dysfunction-free survival (ie, alive with fully functional larynx) at 5-year follow-up. IMRT achieved better tumor control and DSS in patients who had larynx preservation than conventional RT did. Furthermore, patients who received induction and/or concurrent chemotherapy for larynx preservation had better tumor control and long-term survival than patients who received no chemotherapy. Intriguingly, the outcomes of patients who had induction chemotherapy followed by concurrent CRT seemed to be better than those of patients who had upfront concurrent CRT or induction chemotherapy followed by RT alone. Abbreviations: LP-CRT, larynx preservation with induction and/or concurrent chemoradiotherapy; LP-RT, larynx preservation with definitive RT alone; TL-PORT, total laryngectomy followed by postoperative radiotherapy; PEG, percutaneous endoscopic gastrostomy tube; DHT, Dobhoff tube. * Aspiration is recorded as "any-event" aspiration during the posttreatment follow-up. † Aspiration in TL-PORT is caused by leak around the voice prosthesis. Note: All data are number of events/number at risk (%).
Larynx preservation with CRT became an alternative to total laryngectomy after the landmark VA and RTOG trials 1,2 in the 1980s and 1990s, but only came of age with the dissemination of these trials' data in the mid-1990s and early 2000s. 17 Simultaneously, advances in RT were made, and IMRT, with its unmatched conformality and lower toxicity, demonstrably improved survival outcomes in patients with head and neck cancer.
14 Consequently, the current standard of care for patients with T3 laryngeal cancers who have good laryngeal and swallowing function is laryngeal preservation surgery or CRT with IMRT.
Several reports have implied that nonsurgical therapy conveys a decrement in survival and tumor control outcomes. [3] [4] [5] [6] [7] For example, Hoffman et al, 3 using a robust NCDB, reported that increased use of nonsurgical approaches for larynx preservation was concurrent with decreased relative survival in patients with T3 laryngeal cancers. However, because Hoffman et al 3 culled data from between 1985 and 2001, before the implementation of IMRT and the publication of RTOG 9001 and the more widespread use of induction and concurrent chemotherapy, their findings, although timely when published, do not accurately reflect the use of RT and combined modality techniques in the current era. Our findings agree with the notion that radiation without chemotherapy is no panacea. Although IMRT can reduce the radiation dose to swallowing structures, 18, 19 conceivably leading to improved functional outcomes, optimal larynx preservation seems to also have a formal chemotherapy component. In both the present study and the study by Hoffman et al, 3 outcomes achieved with RT alone were worse than those achieved with other therapy regimens. In contrary to the results previously reported by Dziegielewski et al 5 and Chen and Halpern, 6 our results showed that the LP-CRT cohort was associated with lower mortality risk compared to the TL-PORT cohort (HR 5 0.74; p 5 .03; Figure 5 ). The outcomes of treatment of the subset of patients with T3 laryngeal cancer with N0 disease reported by Megwalu and Sikora, 7 showed inferior 5-year OS (48% vs 59%) and DSS (63% vs 69%) for larynx preservation compared to the surgical cohort. However, the discrimination between IMRT and conventional RT is not possible, and dichotomizing RT alone and CRT for larynx preservation cannot be performed in this Surveillance, Epidemiology, and End Results database. For this reason, the differences between the surgical and nonsurgical cohorts potentially obscure radical shifts in therapy that occurred during the long period sampled ). For instance, a patient whose disease was staged using physical examination alone and who was treated with opposed lateral fields on a Cobalt-60 unit in 1973 and a patient whose disease was staged using thin-slice angled-gantry CT for local staging and positron emission tomography-CT for nodal assessment and who was treated with induction chemotherapy followed by concurrent CRT with daily image-guided IMRT in 2009 could both be included in the same "non-surgical" cohort, but this type of classification would be unlikely to provide insight into the specifics of modern management. In our series, the T3N0M0 subset treated with "non-surgical" approaches did no worse in terms of OS, with no observed statistical difference between RT alone or chemoradiation and surgical patients. However, post hoc assessment showed a demonstrable difference (p 5 .03; Supplementary Figure S5 , online only) between the RT alone and the CRT cohorts favoring CRT.
In the present study, we attempted to broadly ascertain whether the chemotherapy component of treatment (induction chemotherapy followed by RT, concurrent CRT, or induction chemotherapy followed by concurrent CRT) had distinct outcome profiles. Our findings suggest that the outcome profiles are substantially different, with induction chemotherapy followed by CRT eliciting better survival outcomes. Our long-term data suggest that the different chemotherapy approaches are associated with distinct patterns of failure, with induction chemotherapy primarily reducing distant failure and concurrent CRT improving locoregional control. Interestingly, our analysis of noncancer-related death, using noncancer cause specific survival as an endpoint, revealed that concurrent CRT resulted in a decrease in noncancer survival, although a similar decrease was not observed in patients receiving induction chemotherapy followed by concurrent CRT (Supplementary Figure S3, online only) .
Data from our facility, as well as those from the VA and RTOG 91-11 trials, suggest that larynx preservation approaches elicit exceedingly poor functional and comparatively worse oncologic outcomes than TL-PORT does in patients with T4 cancers with demonstrable cartilage penetration. 20 On the basis of our experience, we believe that, in general, patients with T3 laryngeal cancer who are candidates for larynx preservation are more likely to benefit from chemotherapy and IMRT, whereas most patients with T4 disease require upfront TL-PORT. In addition, we eschew larynx preservation in both patients with T3 and T4 laryngeal cancer who, on pretreatment barium swallow test, have poor baseline airway functions, such as demonstrable aspiration to a degree that suggests that airway protection after therapy is not possible. For this reason, careful multidisciplinary evaluation, including direct pretherapy assessment by medical oncology, head and neck surgery, radiation oncology, and experienced speech pathology personnel, is the cornerstone of our process for selecting patient-specific therapy.
The present study was not without limitations. The typical caveats of any retrospective analysis apply (eg, selection bias for induction/concurrent chemotherapy, unequal distribution of N classifications in the 3 cohorts, or increased disposition for surgery in previously tracheostomized patients). Although performance status, age, and sex were well-balanced across the cohorts, the nature of our patient-specific multidisciplinary conferences to drive longitudinal care practices is potentially an occult confounder, as our informal consensus has shifted over the decades with regard to therapeutic selection. On the basis of early work from Maccomb and Fletcher, 21 Jesse, 22 and Terhaard et al, 23 surgery alone has not been a routinely used therapy for T3 laryngeal cancer at our institution since the mid-1970s. Therefore, because the earliest records we reviewed in the present study dated to only the mid-1980s, we could not investigate this surgeryalone cohort to determine how its outcomes compared with those of the archaic RT-alone cohorts. Other unidentified confounders, such as technical progress in CT-based imaging, refined surgical approaches, improved speech pathology practices, and demographic and staging shifts likely inflated the role of modern chemotherapy/ IMRT in improving survival outcomes. Finally, we could not investigate the role of larynx conservation surgery versus the nonsurgical approaches because larynx conservation surgery is not considered the standard surgical approach for T3 disease in our institution.
Despite its potential limitations, our study represents, to our knowledge, the largest single-site retrospective series of patients with T3 laryngeal cancer in the modern era. Furthermore, because our study analyzed multiple relevant oncologic, functional, and survival endpoints simultaneously and was sufficiently numerically robust to detect significant between-cohort differences, our study's findings can be used to guide future prospective studies, such as those evaluating the use of induction or concurrent CRT for larynx preservation in patients with T3 laryngeal cancer. We aim to implement this data for advanced riskstratification in future studies investigating novel chemotherapy agents or RT techniques. To conclude, in patients with T3 laryngeal cancers, modern larynx preservation regimens using both chemotherapy and RT, in addition to providing satisfactory long-term functional outcomes, resulted in comparatively better oncologic outcomes than historical approaches utilizing laryngectomy plus adjuvant RT or RT alone. Such modern approaches should be considered the preferred standard of care for both therapy selection and future outcome assessment.
